Allergy Therapeutics (AGY)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 14.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 15.20
  • 52 Week Low: 7.38
  • Currency: UK Pounds
  • Shares Issued: 637.29m
  • Volume: 26,267
  • Market Cap: 90.81m
  • RiskGrade: 258

AGY Overview

Allergy Therapeutics is in the pharma and biotech sector and is currently trading at 14.25p per share. In the last year Allergy Therapeutics's share price has ranged from 7.38p to 15.20p and brokers are currently rating this stock as 'strong buy'.

1 Day Chart (03-08-2020)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 6.0% 4.7%
ROCE 12.3%  
Latest F'cast
P/E 25.9 32.6
PEG n/a n/a
Pr/Revenue 1.2 1.2
Pr/Book 2.4  
Latest F'cast
Revenue 7.9% 6.1%
PBT n/a -14.0%
EPS n/a -20.5%
DPS n/a n/a

AGY Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-15 43.00 0.65 0.02p 1,093.7 n/a -88% n/a 0.0%
30-Jun-16 48.51 (12.06) (2.29)p n/a n/a n/a n/a 0.0%
30-Jun-17 64.14 (2.48) (0.42)p n/a n/a n/a n/a 0.0%
30-Jun-18 68.35 (6.90) (1.27)p n/a n/a n/a n/a 0.0%
30-Jun-19 73.72 4.29 0.55p 25.5 n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AGY Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 78.20 3.69 0.44p 32.6 n/a -20% n/a 0.0%
30-Jun-21 83.65 (7.99) (1.44)p n/a n/a n/a n/a 0.0%

Copyright © 2020 FactSet Research Systems Inc. All rights reserved.

AGY Company Announcements

Second Price Monitoring Extn 15-Jul-2020 11:05 RNS
Price Monitoring Extension 15-Jul-2020 11:00 RNS
Trading Update 15-Jul-2020 07:00 RNS

Latest AGY Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AGY Market Data

Currency UK Pounds
Share Price 14.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 15.20
52 Week Low 7.38
Volume 26,267
Shares Issued 637.29m
Market Cap 90.81m
RiskGrade 258

AGY Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
79.41% below the market average79.41% below the market average79.41% below the market average79.41% below the market average79.41% below the market average
53.57% above the sector average53.57% above the sector average53.57% above the sector average53.57% above the sector average53.57% above the sector average
Price Trend
38.66% above the market average38.66% above the market average38.66% above the market average38.66% above the market average38.66% above the market average
12.28% above the sector average12.28% above the sector average12.28% above the sector average12.28% above the sector average12.28% above the sector average
Income Not Available
Growth
4.39% above the market average4.39% above the market average4.39% above the market average4.39% above the market average4.39% above the market average
37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AGY Dividends

No dividends found

Trades for 03-Aug-2020

Time Volume / Share Price
16:11 13,690 @ 14.55p
08:59 6,814 @ 13.75p
08:23 4,408 @ 14.63p
08:09 1,355 @ 13.75p

AGY Key Personnel

CEO Manuel Llobet
Finance Director Nicolas Wykeman

Top of Page